MedPAN is offering a training course on Developing and implementing a fundraising strategy for Marine Protected Areas.

This training is intended for MPA management bodies, NGOs with a formal mandate to co-manage an MPA, national or local MPA authorities, and networks of MPA managers.

The training is designed in a hybrid format, combining e-learning and face-to-face sessions:

  • 14-22 September 2022 | distance learning session: This preliminary phase of the training (combining self-directed learning and three 90-minute supervised online sessions) will provide trainees with an initial theoretical grounding in fundraising.
  • 26-29 September 2022, Monastir, Tunisia | face-to-face session: This second 4-day training phase will enable learners to develop practical skills to implement their own fundraising strategy.

Throughout the training, participants will work on a dedicated tool for the development of a fundraising strategy for Marine Protected Areas. This turnkey tool will be presented to participants at the beginning of the e-learning session and will be completed throughout the course. At the end of the course, participants will have formalised a preliminary fundraising strategy. 

Apply for the training and receive the email with instructions on how to submit your training application by Tuesday 26 July 2022.

If you have any questions about this training, please contact Pierre Vignes, MedPAN Secretariat

We hope that this training opportunity will meet your needs and contribute to effective MPAs.


This training was developed in association with APAL (Agence de Protection et d’Aménagement du Littoral, Tunisia) / Notre Grand Bleu (NGO co-manager of the Kuriat Islands MCPA (Tunisia) and Brijuni National Park (Croatia) with the technical support of RIO Impact. The training is funded by the MAVA Foundation (MPA/no-take project), the FFEM COGITO project, the ENI CBC Med ENSERES project, Sigrid Rausing Trust, the LIFE Programme of the European Union, the OFB (French Biodiversity Office), the City of Marseille and CD13.

Tagged on: